Predictors of better response to radioligand therapy of metastatic castrate-resistantprostate cancer with 177Lu-PSMA-617

Conclusions RLT with Lu-PSMA is an effective therapy in hormone-refractory patients. The metastases should be just PSMA-positive but the response is independent of the amount of PSMA expression. A better treatment response was observed in older patients with a lower Gleason score as well as in patients with platelets in the lower normal limit and without regular need for pain medication.

Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: Ferdinandus, J., Eppard, E., Kuerpig, S., Gaertner, F., Fimmers, R., Hauser, S., Essler, M., Ahmadzadehfar, H. Tags: MTA I: Radiopharmaceutical Therapy Posters Source Type: research